# Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

> **NCT02852798** · — · UNKNOWN · sponsor: **Jiangsu ShengDiYa Medicine Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Nonsquamous Nonsmall Cell Neoplasm of Lung

## Interventions

- **DRUG:** Apatinib Combined With Docetaxel

## Key facts

- **NCT ID:** NCT02852798
- **Lead sponsor:** Jiangsu ShengDiYa Medicine Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2017-08
- **Final completion:** 2018-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02852798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02852798, "Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02852798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*